Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer
Addition of Immunotherapy in Lung Cancer The addition of pembrolizumab to chemotherapy for metastatic lung cancer without EGFR or ALK mutations resulted in better progression-free and overall survival than chemotherapy alone. Immune-related adverse effects were more common with the combination.
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
April 16, 2018
|
| In: |
The New England journal of medicine
Year: 2018, Jahrgang: 378, Heft: 22, Pages: 2078-2092 |
| ISSN: | 1533-4406 |
| DOI: | 10.1056/NEJMoa1801005 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1056/NEJMoa1801005
|
| Verfasserangaben: | L. Gandhi, D. Rodríguez‑Abreu, S. Gadgeel, E. Esteban, E. Felip, F. De Angelis, M. Domine, P. Clingan, M.J. Hochmair, S.F. Powell, S.Y.-S. Cheng, H.G. Bischoff, N. Peled, F. Grossi, R.R. Jennens, M. Reck, R. Hui, E.B. Garon, M. Boyer, B. Rubio‑Viqueira, S. Novello, T. Kurata, J.E. Gray, J. Vida, Z. Wei, J. Yang, H. Raftopoulos, M.C. Pietanza, and M.C. Garassino, for the KEYNOTE-189 Investigators |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1685464459 | ||
| 003 | DE-627 | ||
| 005 | 20220817184536.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 191213s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1056/NEJMoa1801005 |2 doi | |
| 035 | |a (DE-627)1685464459 | ||
| 035 | |a (DE-599)KXP1685464459 | ||
| 035 | |a (OCoLC)1341282019 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Gandhi, Leena |e VerfasserIn |0 (DE-588)1201577209 |0 (DE-627)1685467369 |4 aut | |
| 245 | 1 | 0 | |a Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer |c L. Gandhi, D. Rodríguez‑Abreu, S. Gadgeel, E. Esteban, E. Felip, F. De Angelis, M. Domine, P. Clingan, M.J. Hochmair, S.F. Powell, S.Y.-S. Cheng, H.G. Bischoff, N. Peled, F. Grossi, R.R. Jennens, M. Reck, R. Hui, E.B. Garon, M. Boyer, B. Rubio‑Viqueira, S. Novello, T. Kurata, J.E. Gray, J. Vida, Z. Wei, J. Yang, H. Raftopoulos, M.C. Pietanza, and M.C. Garassino, for the KEYNOTE-189 Investigators |
| 264 | 1 | |c April 16, 2018 | |
| 300 | |a 15 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 13.12.2019 | ||
| 520 | |a Addition of Immunotherapy in Lung Cancer The addition of pembrolizumab to chemotherapy for metastatic lung cancer without EGFR or ALK mutations resulted in better progression-free and overall survival than chemotherapy alone. Immune-related adverse effects were more common with the combination. | ||
| 700 | 1 | |a Bischoff, Helge |d 1958- |e VerfasserIn |0 (DE-588)111184576 |0 (DE-627)389658286 |0 (DE-576)167287249 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The New England journal of medicine |d Waltham, Mass. : MMS, 1928 |g 378(2018), 22, Seite 2078-2092 |h Online-Ressource |w (DE-627)266889484 |w (DE-600)1468837-2 |w (DE-576)075962454 |x 1533-4406 |7 nnas |a Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer |
| 773 | 1 | 8 | |g volume:378 |g year:2018 |g number:22 |g pages:2078-2092 |g extent:15 |a Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer |
| 856 | 4 | 0 | |u https://doi.org/10.1056/NEJMoa1801005 |x Verlag |x Resolving-System |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20191213 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 111184576 |a Bischoff, Helge |m 111184576:Bischoff, Helge |d 910000 |d 950000 |d 950900 |e 910000PB111184576 |e 950000PB111184576 |e 950900PB111184576 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 12 | ||
| 999 | |a KXP-PPN1685464459 |e 3564571302 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 13.12.2019"],"title":[{"title_sort":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer"}],"origin":[{"dateIssuedKey":"2018","dateIssuedDisp":"April 16, 2018"}],"relHost":[{"origin":[{"publisher":"MMS ; MMS","dateIssuedKey":"1928","publisherPlace":"Waltham, Mass. ; Boston, Mass.","dateIssuedDisp":"1928-"}],"title":[{"subtitle":"NEJM","title":"The New England journal of medicine","title_sort":"New England journal of medicine"}],"note":["Gesehen am 04.08.25"],"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"recId":"266889484","physDesc":[{"extent":"Online-Ressource"}],"disp":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancerThe New England journal of medicine","pubHistory":["198.1928 -"],"titleAlt":[{"title":"NEJM"}],"name":{"displayForm":["Massachusetts Medical Society"]},"corporate":[{"role":"isb","display":"Massachusetts Medical Society"}],"part":{"volume":"378","year":"2018","issue":"22","text":"378(2018), 22, Seite 2078-2092","extent":"15","pages":"2078-2092"},"id":{"zdb":["1468837-2"],"eki":["266889484"],"issn":["1533-4406"]}}],"person":[{"display":"Gandhi, Leena","role":"aut","given":"Leena","family":"Gandhi"},{"family":"Bischoff","role":"aut","given":"Helge","display":"Bischoff, Helge"}],"physDesc":[{"extent":"15 S."}],"recId":"1685464459","id":{"eki":["1685464459"],"doi":["10.1056/NEJMoa1801005"]},"name":{"displayForm":["L. Gandhi, D. Rodríguez‑Abreu, S. Gadgeel, E. Esteban, E. Felip, F. De Angelis, M. Domine, P. Clingan, M.J. Hochmair, S.F. Powell, S.Y.-S. Cheng, H.G. Bischoff, N. Peled, F. Grossi, R.R. Jennens, M. Reck, R. Hui, E.B. Garon, M. Boyer, B. Rubio‑Viqueira, S. Novello, T. Kurata, J.E. Gray, J. Vida, Z. Wei, J. Yang, H. Raftopoulos, M.C. Pietanza, and M.C. Garassino, for the KEYNOTE-189 Investigators"]}} | ||
| SRT | |a GANDHILEENPEMBROLIZU1620 | ||